CSL Limited CSLLY
34.61 USD +0.16 (+0.46%)
Nov 11, 2026, 3:49 PM EST
34.37 Day range 34.61
16.01 52-week range 36.88
- YTD
- +20.17%
- 1 year
- +19.10%
- Market cap
- 66.44B
- EPS (ttm)
- -1.34
- YTD return
- +20.17%
- 1-year return
- +19.10%
- Volume
- 2.37K
- Avg volume
- 87.10K
- Open
- 34.37
- Previous close
- 34.45
- Day's range
- 34.37 – 34.61
- 52-week range
- 16.01 – 36.88
5D -0.49 (-1.40%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2026 | Dec 31, 2025 | — | 0.055 | — | — |
| Feb 10, 2025 | Dec 31, 2024 | — | 0.2594 | — | — |
News
BROAD ARROW'S ZÜRICH AUCTION CONCLUDES A REMARKABLE 2026 AUCTION CALENDAR 
CSL Limited (CSLLY) Shareholder/Analyst Call Transcript 
CSL appoints Deborah Waterhouse as CEO & Managing Director 
Australia's CSL appoints Deborah Waterhouse as CEO 
HRMY vs. CSLLY: Which Stock Is the Better Value Option? 
CSL y Alentis desarrollarán y comercializarán lixudebart para enfermedades renales y hepáticas raras 
CSL strikes US$1.6 billion licensing deal for rare disease drug 
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis 
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases 
Australia's CSL taps Amazon's cloud unit to boost research pipeline
Your note
Sign in to keep a note on CSLLY — it syncs with the Stock Master app.